Turn Biotechnologies
Biotechnology company developing mRNA therapeutics with lipid nanoparticle delivery, focusing on reprogramming the epigenome to restore cellular functions lost with age through ERA (Epigenetic Reprogramming of Aging) technology.
Notes
Turn Biotechnologies (Turn.Bio) is a biotechnology company developing mRNA medicines that instruct specific cells to fight disease or repair damaged tissue. The company is headquartered in Mountain View, California.
Turn's proprietary ERA (Epigenetic Reprogramming of Aging) technology uses mRNA therapeutics delivered via lipid nanoparticles to reprogram the epigenome and restore cellular functions lost with age. This approach aims to:
- Reverse cellular aging
- Restore youthful gene expression patterns
- Rejuvenate aged tissues
- Treat age-related diseases
The company has received funding from VitaDAO, a decentralized autonomous organization focused on longevity research.
Team
- Vittorio Sebastiano, Ph.D. - Co-founder & Chief Scientific Officer
- Stanford University faculty
- Anja Krammer - Chief Executive Officer
Additional Research Findings
- ERA (Epigenetic Reprogramming of Aging) technology
- mRNA therapeutics with lipid nanoparticle delivery
- Epigenome reprogramming focus
- Funded by VitaDAO
- Age-related disease therapeutics
- Mountain View, California headquarters
- Founded in 2018
- Stanford University spinout
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |